<DOC>
	<DOCNO>NCT02349295</DOCNO>
	<brief_summary>The main purpose study evaluate effective safe study drug know ixekizumab participant active psoriatic arthritis .</brief_summary>
	<brief_title>A Study Ixekizumab ( LY2439821 ) Participants With Active Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Presents establish diagnosis active psoriatic arthritis ( PsA ) least 6 month , currently meet Classification Psoriatic Arthritis ( CASPAR ) criterion Active PsA define presence least 3 tender least 3 swollen joint Presence active psoriatic skin lesion history plaque psoriasis ( Ps ) Men must agree use reliable method birth control remain abstinent study Women must agree use reliable birth control remain abstinent study least 12 week stop treatment Have treat 1 conventional diseasemodifying antirheumatic drug ( cDMARDs ) Current use biologic agent treatment Ps PsA Inadequate response great 2 biologic DMARDs Current use one cDMARDs Diagnosis active inflammatory arthritic syndrome spondyloarthropathies PsA Have receive treatment interleukin ( IL ) 17 IL12/23 target monoclonal antibody ( MAb ) therapy Serious disorder illness psoriatic arthritis Serious infection within last 3 month Breastfeeding nursing ( lactate ) woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>